Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 18/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.49 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.47 |
| ▸ | VEGFA | P15692 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921887 | 0.81 | EGLN1 (0.65) | EGLN1KDM4EMAPK1FTOEGLN3 | |
| SCHEMBL19808953 | 0.81 | EGLN1 (1.00) | EGLN1FTOEGLN3VEGFAFLT1 | |
| SCHEMBL20117480 | 0.80 | EGLN1 (0.72) | EGLN1FTOEGLN3VEGFAFLT1 | |
| SCHEMBL19823597 | 0.80 | EGLN1 (1.00) | EGLN1FTOEGLN3 | |
| SCHEMBL20117504 | 0.80 | EGLN1 (0.72) | EGLN1FTOEGLN3VEGFAFLT1 | |
| SCHEMBL20117478 | 0.80 | EGLN1 (0.80) | EGLN1FTOEGLN3VEGFAFLT1 | |
| SCHEMBL20117624 | 0.80 | EGLN1 (0.80) | EGLN1FTOEGLN3VEGFAFLT1 | |
| SCHEMBL20110583 | 0.80 | EGLN1 (0.84) | EGLN1FTOEGLN3VEGFAFLT1 | |
| SCHEMBL30274480 | 0.78 | EGLN1 (0.73) | EGLN1 | |
| SCHEMBL2537376 | 0.78 | EGLN1 (0.73) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180117021-A1 | COMPOUND OF 3-HYDROXYL PYRIDINE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117021-A1 | COMPOUND OF 3-HYDROXYL PYRIDINE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | EGLN3, EGLN2, P4HA1 | EGLN1 6/4885KDM4E 409/4885MAPK1 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.